MASH is a multifactorial disease, and PPAR agonists may need to be combined with other agents, such as GLP-1 receptor agonists, fibroblast growth factor 21 (FGF21) analogs, or antifibrotic drugs, to achieve the best outcomes. This evidence concerns the gene PPARA and metabolic dysfunction-associated steatohepatitis.